← Human Trials & Peer-Reviewed Studies
North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.
Plain-language guide to PMID 25423327 (2015): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 25423327
- Journal
- Menopause (New York, N.Y.)
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Park H et al. (13 authors)
- DOI
- 10.1097/GME.0000000000000374
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
Hot flashes are a common symptom in breast cancer survivors that can negatively impact quality of life.
Who Took Part
The age groups tagged for this paper are middle-aged adults, women only.
The primary endpoint was intrapatient difference in mean hot flash score between baseline and treatment periods, comparing each magnesium group with the combined placebo groups using a gatekeeping procedure.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
A four-arm, double-blind, placebo-controlled, randomized trial was conducted.
Hot flash frequency and hot flash score (number × mean severity) were measured using a validated hot flash diary.
A 1-week baseline period preceded initiation of study medication.
What Was Measured
Topics PubMed links to this paper include Breast Neoplasms, Dietary Supplements, Hot Flashes, Magnesium Oxide, Menopause and Quality of Life.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2015 (Menopause (New York, N.Y.)), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.